Form 4: Michael Knell Trades Charles River Labs Stock
Statement of Changes in Beneficial Ownership
Michael Knell, SVP, Finance and CAO of Charles River Laboratories International, Inc., reported transactions involving common stock, including acquisitions and dispositions.
Summary
- Michael Gunnar Knell, SVP, Finance and CAO of Charles River Laboratories International, Inc. (CRL), reported transactions on May 29, 2026, May 30, 2026, and May 31, 2026.
- On May 29, 2026, 1,837 shares of common stock were acquired at a price of $180.71 per share.
- Following this acquisition, Mr. Knell beneficially owned 16,352 shares of common stock.
- On May 30, 2026, 152 shares of common stock were disposed of at a price of $180.71 per share.
- On May 31, 2026, 48 shares of common stock were disposed of at a price of $180.71 per share.
- After these dispositions, Mr. Knell beneficially owned 16,200 shares on May 30 and 16,152 shares on May 31.
- The filing also notes that unvested restricted stock units (RSUs) vest annually on May 29, 2027, May 29, 2028, May 29, 2029, and May 29, 2030.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine insider stock transactions and vesting schedules without significant positive or negative financial news.
Positives
- Acquisition of 1,837 shares of common stock on May 29, 2026, indicating continued investment or compensation.
- The reporting person holds a significant number of shares (16,152 as of May 31, 2026), suggesting long-term commitment.
Negatives
- Disposition of 152 shares on May 30, 2026, and 48 shares on May 31, 2026, indicating some reduction in holdings.
Future Outlook
The filing indicates that unvested restricted stock units will vest annually through May 29, 2030, suggesting a structured compensation plan with future equity grants.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions at publicly traded companies like Charles River Laboratories, providing transparency into executive stock dealings.
Stakeholder Impact
- Shareholders: The transactions provide insight into executive stock ownership and potential selling pressure, though the amounts are relatively small compared to total outstanding shares.
Next Steps
- Continued annual vesting of restricted stock units through May 29, 2030.
Key Dates
| Date | Description |
|---|---|
| 05/29/2026 | Earliest transaction date reported; acquisition of 1,837 shares of common stock. |
| 05/29/2027 | First vesting date for a portion of unvested restricted stock units. |
| 05/29/2028 | Second vesting date for a portion of unvested restricted stock units. |
| 05/29/2029 | Third vesting date for a portion of unvested restricted stock units. |
| 05/29/2030 | Fourth and final vesting date for unvested restricted stock units. |
| 05/30/2026 | Disposition of 152 shares of common stock. |
| 05/31/2026 | Disposition of 48 shares of common stock. |
| 06/02/2026 | Date of signature for the filing. |
Keywords
Form 4, SEC Filing, Insider Trading, Stock Transaction, Charles River Laboratories, CRL, Michael Knell, Beneficial Ownership, Restricted Stock Units, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.